Original language | English |
---|---|
Pages (from-to) | 1117-1120 |
Number of pages | 4 |
Journal | Blood |
Volume | 137 |
Issue number | 8 |
DOIs |
|
Publication status | Published - 25 Feb 2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Blood, Vol. 137, No. 8, 25.02.2021, p. 1117-1120.
Research output: Contribution to journal › Comment/Letter to the editor › Academic
TY - JOUR
T1 - Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
AU - Niemann, Carsten U.
AU - Levin, Mark-David
AU - Dubois, Julie
AU - Kersting, Sabina
AU - Enggaard, Lisbeth
AU - Veldhuis, Gerrit J.
AU - Mous, Rogier
AU - Mellink, Clemens H. M.
AU - Dobber, Johan A.
AU - Poulsen, Christian B.
AU - Frederiksen, Henrik
AU - Janssens, Ann
AU - Schjødt, Ida
AU - Dompeling, Ellen C.
AU - Ranti, Juha
AU - Mattsson, Mattias
AU - Bellido, Mar
AU - Tran, Hoa T. T.
AU - Nasserinejad, Kazem
AU - Kater, Arnon P.
N1 - Funding Information: The work was supported by AbbVie and Janssen who also provided study drugs and had the option to comment on the manuscript. Funding Information: The authors thank all participating patients, local data managers for study coordination and patient data collection, local investigators, and, in particular, the study team at the HOVON Data Center at the Erasmus MC Cancer Institute and the 2 central laboratories at Amsterdam UMC and Rigshospitalet. The work was supported by AbbVie and Janssen who also provided study drugs and had the option to comment on the manuscript. The investigators are independent data owners with unrestricted publication rights. Funding Information: Conflict-of-interest disclosure: A.P.K. received research funding and consultancy fees from AbbVie and Janssen and a speaker's fee from AbbVie. J.D. received research funding from AbbVie. C.U.N. received research funding from the Novo Nordisk Foundation (grant NNF16OC0019302) and research support, consultancy fees, and/or travel grants from AbbVie, Gilead, Janssen, Roche, CSL Behring, Genmab, Sunesis, and Acerta/Astra Zeneca outside of this work. M.-D.L. received travel support and consultancy fees from AbbVie, Janssen, and Roche. S.K. received travel support from Cellgene. H.F. received research funding from Novartis, Alexion, Gilead, and AbbVie outside of this work. H.T.T.T. received consultancy fees from AbbVie, Pfizer, and Janssen; speaker's fees from Novartis and Janssen; and research funding from CSL Behring. The remaining authors declare no competing financial interests.
PY - 2021/2/25
Y1 - 2021/2/25
UR - http://www.scopus.com/inward/record.url?scp=85100802986&partnerID=8YFLogxK
U2 - https://doi.org/10.1182/blood.2020008608
DO - https://doi.org/10.1182/blood.2020008608
M3 - Comment/Letter to the editor
C2 - 33027809
SN - 0006-4971
VL - 137
SP - 1117
EP - 1120
JO - Blood
JF - Blood
IS - 8
ER -